PDCD1LG2 and cancer: The ability of cancer cells to evade T cell responses and avoid immune recognition by disabling effector T cells is dependent on the multiple immunosuppressive mechanisms controlled by immune checkpoints of inhibitory pathways, including, but not limited to, programmed death-ligand (PD-L)1 and PD-L2.